

	Hall 1	Hall 2	15.3	Hall 15.2	Hall 3	Hall 7	Roof Garden
			11.00 - 13.30 Novartis Oncology Satellite Symposium	11.00 - 13.00 Prime Oncology Satellite Symposium	11.00 - 13.00 Lilly Oncology Satellite Symposium	11.00 - 13.00 Wyeth Pharmaceuticals Satellite Symposium	11.00 - 13.00 Hospira Satellite Symposium
	13.00 - 15.00 Astrazeneca Satellite Symposium	14.00 - 16.00 Novartis Oncology Satellite Symposium	14.00 - 16.00 Pfizer Oncology Satellite Symposium	14.00 - 17.00 Roche Satellite Symposium	14.00 - 16.00 Helsinn Healthcare SA Satellite Symposium	14.00 - 16.00 MSD Oncology Satellite Symposium	
	17.30 - 19.00 Mereck Serono Satellite Symposium	17.00 - 19.00 Novartis Oncology Satellite Symposium	17.00 - 19.00 Prime Oncology Satellite Symposium			17.00 - 19.00 Bristol-Myers Squibb Satellite Symposium	17.00 - 19.00 Cephalon Europe Satellite Symposium

19:00	<b>Opening Event</b>
	Welcome Reception with Music and Presentations

Session Abbreviations

- T.L: Teaching lecture
- E.S. : Educational Symposium
- P.S. : Poster Session
- P.P.: Proffered Papers Session
- Sc. S.: Scientific Symposium
- Soc. S.: Society Session
- Spec. S. : Special Session

	Hall 1	Hall 2	Hall 15.2	Hall 3	Hall 15.1	Hall 15.3	Stage	Roof Garden	Hall 7	Hall 14.2	Hall 4/5	Hall 9	Hall 10	Hall 8		
08:00		T.L. <b>Breast</b>	T.L. <b>Colorectal</b>	T.L. <b>Lung</b>	T.L. <b>GU-prostate</b>	T.L. <b>Radiotherapy</b>	T.L. <b>Nursing</b>		T.L. <b>Head and Neck</b>	T.L.	T.L. <b>Haem.</b>	T.L. <b>Basic science</b>	T.L. <b>Surgical oncol</b>	T.L. <b>Paediatric</b>		
08:45		Challenges of neoadj. chemo in breast cancer	Genomic profiling	Lung cancer screening	New agents for metastatic prostate cancer	Hadron therapy	Are we assessing what is important for patients and families?		Clinical relevance of HPV		Therapy of DLCL	MicroRNA's and their antagonists as novel therapeutics	Image guided surgery	New approaches to clinical trial design for rare tumours		
08:55	<b>Opening</b>															
10:50	<b>Opening session</b>															
11:00	P.P. <b>Breast</b>	P.P. <b>Colorectal</b>	P.P. <b>Lung</b>	P.P. <b>GU-prostate</b>	Sc. S. <b>Basic science</b>	Soc. S. <b>ESTRO</b>	Sc. S. <b>Nursing</b>	Sc. S. <b>Regulatory</b>	P.P. <b>Nursing</b>	Advocacy <b>Patients</b>	P.P. <b>Haem.</b>			Soc. S. <b>SIOPE</b>		
13:00	Proffered papers	Proffered papers	Proffered papers	Proffered papers	The hypoxia pathway in tumour progression and therapy	European Society of Therapeutic Radiology and Oncology	Symptom clusters in cancer therapy	Methodology and regulatory aspects of biotherapeutics and chemotherapeutics	Proffered papers	Patient groups - meeting the challenge of sustainable funding	Proffered papers			European Society of Paediatric Oncology award + proffered papers		
13:15	<b>Presidential I</b>											<b>Young Oncol.</b>				
14:00												Poster discussion				
15:00												13:30-15:00				
16:00												<b>Advocacy</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Spec. S.</b>
16:15	<b>E. S.</b> <b>Breast</b>	<b>E. S.</b> <b>Colorectal</b>	<b>Sc. S.</b> <b>Lung</b>	<b>Sc. S.</b> <b>GU-prostate</b>	<b>Sc. S.</b> <b>Translational</b>	<b>Sc. S.</b> <b>Radiotherapy</b>	<b>Sc. S.</b> <b>Nursing</b>	<b>Sc. S.</b> <b>Head and Neck</b>	<b>Sc. S.</b> <b>Surgical oncol.</b>	<b>Advocacy</b> <b>Patients</b>	<b>Sc. S.</b> <b>Haem.</b>	<b>P.P.</b> <b>Nursing</b>		<b>Sc. S.</b> <b>Paediatric</b>		
18:15	Clinical relevance of triple negative breast cancer concept	Systemic treatment of adv. colorectal cancer	Genetic aberrations in lung cancer	Prostate cancer	Resistance mechanisms to EGFR and HER2 inhibitors	GENEPI: Genetic prediction of radiation damage	After cancer therapy, prevention and promotion	Head and Neck cancer treatment: how aggressive should we be?	QA and audit in colorectal cancer in Europe	Access to clinical trials	New drugs and novel therapeutics for Haem. Malig.	Proffered papers		How to select a new drug in Paediatric oncology		
	<b>18.30 - 20.00</b> Pfizer Oncology Satellite Symposium		<b>18.30 - 20.00</b> Prime Oncology Satellite Symposium		<b>18.30 - 20.00</b> Bayer Schering Pharma Satellite Symposium		<b>18.30 - 20.00</b> Schering Plough Satellite Symposium		<b>18.30 - 20.00</b> GlaxoSmithKline Oncology Satellite Symposium							

**P.S. I**  
Central Nervous system, Drug Development: Phase I and II, Preclinical, Translational research

**P.S. II**  
Gu-Other, Gu - Renal, Cancer in the older Individual , Basic science,

**Nursing poster viewing (09.00-17.00)**

	Hall 1	Hall 2	Hall 15.2	Hall 3	Hall 15,1	Hall 15.3	Stage	Roof Garden	Hall 7	Hall 14.2	Hall 4/5	Hall 9	Hall 10	Hall 8			
	<b>HIGHLIGHTS</b>	<b>T.L.</b>	<b>T.L.</b>	<b>T.L.</b>	<b>T.L.</b>	<b>T.L.</b>	<b>T.L.</b>		<b>T.L.</b>	<b>T.L.</b>	<b>T.L.</b>	<b>T.L.</b>	<b>T.L.</b>	<b>T.L.</b>			
08:00	Prostate Cancer, Paediatric Oncology, Haematological Malignancies	<b>Breast</b> Bisphosphate for care and cure	<b>Colorectal</b> The KRAS story and beyond	<b>Lung</b> Chest tumours/ non NSCLC/rare tumours	<b>GU-Prostate</b> PSA screening review of recent studies	<b>Radiotherapy</b> The value of new imaging technology for target volume delineation	<b>Nursing</b> Cancer and nutrition key determinants of QoL		<b>CNS</b> Re-irradiation in Brain Tumours	<b>Surgical oncol.</b> Mission accomplished or work in progress - laparoscopic vs open colorectal surgery	<b>Haem.</b> Allogeneic transplantation	<b>Elderly</b> Biology of cancer and aging	<b>Translational</b> DNA replication proteins as biomarkers	<b>Paediatric</b> Advances in fertility preservation for children with cancer			
08:45																	
09:00	<b>P. P.</b> <b>Breast</b>	<b>P. P.</b> <b>Colorectal</b>	<b>P. P.</b> <b>Lung</b>	<b>Soc. S.</b> <b>ESMO</b>	<b>P. P.</b> <b>GU-other</b>	<b>Oncopolicy</b>	<b>Nursing</b>	<b>Soc. S.</b> <b>EACR</b>	<b>P. P.</b> <b>CNS</b>	<b>Advocacy</b> <b>Patients</b>	<b>Sc. S.</b> <b>Haem.</b>	<b>P. P.</b> <b>Elderly</b>	<b>P. P.</b> <b>Nursing</b>	<b>Sc. S.</b> <b>Paediatric</b>	<b>P.S. III</b>		
11:00	Proffered papers	Proffered papers	Proffered papers	European Society of Medical Oncology Award session	Proffered papers	European Partnership for action against cancer	Researching complex clinical issues in cancer care	European Association for Cancer Research	Proffered papers	The burden of cancer	Role of PET imaging	Proffered papers	Proffered papers	Recent breakthroughs and future breakthroughs	Head and Neck cancer, Haematological malignancies and myeloma, Diagnostic/Biomarkers, GU-Prostate Cancer		
11:15	<b>Keynote</b>			<b>Noncolorectal</b>					11:00	<b>Advocacy</b> <b>Patients</b>							
12:00	Targeting the cell cycle in cancer			Poster discussion (viewing: 09:30-11:00)						From patient to partner: evolution of the patient's role in health							
12:15	<b>Presidential II</b>								12:00								
14:30	<b>Awards, late breaking and best abstracts</b>		13:30	<b>Spec. S</b> <b>Oncopolicy</b>	<b>Spec. S</b> <b>GU-Prostate</b>	<b>Spec. S</b> <b>Radiotherapy</b>	<b>Spec. S</b> <b>Surgical oncol.</b>	<b>Spec. S</b> <b>Nursing</b>	<b>Spec. S</b> <b>Basic science</b>	<b>Debate</b> <b>CNS</b>	<b>Advocacy</b> <b>Patients</b>	<b>Spec. S</b> <b>Elderly</b>	<b>Spec. S</b> <b>Regulatory</b>				
				National cancer plans	Side effects of treatment for early disease	Very late tissue damage after radiotherapy	Management of GIST tumours	Palliative cancer care	Synthetic lethality as a novel strategy of cancer therapy	This house believes that molecular markers are helpful for selecting therapies for	Cancer in the workplace	Breast cancer in the elderly	Individualisation of treatment based on pharmacokinetics and pharmacogenomics		<b>P.S. IV</b>	<b>LATE BREAKING POSTERS (Viewing 11.00-13.00)</b>	
14:45	<b>Sc. S.</b> <b>Breast</b>	<b>E.S.</b> <b>Lung</b>	<b>E.S.</b> <b>GU-Prostate</b>	<b>Sc. S.</b> <b>Colorectal</b>	<b>Sc. S.</b> <b>Radiotherapy</b>	<b>P. P.</b> <b>Head and Neck</b>	<b>Sc. S.</b> <b>Nursing</b>	<b>Sc. S.</b> <b>Basic science</b>	<b>Sc. S.</b> <b>CNS</b>	<b>Advocacy</b> <b>Patients</b>	<b>Sc. S.</b> <b>Elderly</b>	<b>P. P.</b> <b>Nursing</b>	<b>Sc. S.</b> <b>Diagnostic</b>	<b>Sc. S.</b> <b>Paediatric</b>	Symptom science, Melanoma and Skin Cancer, Gynaecological Cancer		
16:45	Targeted therapy in breast cancer	Can there be generalised recommendations for multimodality treatment in stage III NSCLC	Prostate cancer - therapeutic options after relapse	Locally advanced rectal cancer	Biological imaging for adaptive radiotherapy	Proffered papers	Managing emotional concerns	The DNA damage response in cancer: role in tumourigenesis and targeted therapies	Investigating novel targets and anti-angiogenesis agents in brain tumours	Improving cancer outcomes through healthy lifestyle choices	Clinical management of the elderly	Proffered papers	Biomarkers in early clinical development	Refining treatment and the cost of the cure			
17:00	<b>Debate</b> <b>Breast</b>	<b>Debate</b> <b>GU-Prostate</b>	<b>Spec. S</b> <b>Lung</b>	<b>Spec. S</b> <b>Colorectal</b>	<b>Forum</b> <b>Oncopolicy</b>	<b>Debate</b> <b>Head and Neck</b>	<b>Spec. S</b> <b>Nursing</b>	<b>E.S.</b> <b>Translational</b>	<b>Workshop</b>	<b>Debate</b> <b>Patients</b>	<b>Debate</b> <b>Haem.</b>		<b>Debate</b> <b>Diagnostic</b>				
18:00	This house believes that it is appropriate to give adj. chemo. for endocrine responsive tumours	This house believes that radical surgery is better than radical radiation therapy for locally-advanced prostate cancer	Specific issues in lung cancer management	Deficient mismatch repair (dMMR) in colorectal cancer	Optimising drug development: issues for academia, industry and regulatory bodies	This house believes that bio radiation can replace chemo radiation in head and neck cancer	Case-based: critical moments in cancer therapy	All you wanted to know about cancer stem cells but were afraid to ask	Seventh Framework Programme (FP7)	This house believes that individualised treatment will be the future	This house believes that watching and waiting is still an option in indolent lymphomas		This house believes that we should abandon routine embedding of tumour tissues in paraffin		<b>Nursing poster viewing (09.00-17.00)</b>	<b>ESO/ACOE CME Workshop 11.00-18.15 (Invitation only)</b>	
				<b>Societies General Assembly meetings</b>													
	18.30 - 20.00 Merck Serono Satellite Symposium			18.30 - 20.00 Pfizer Oncology Satellite Symposium	18.30 - 20.00 Amgen (Europe) GmbH Satellite Symposium			18.30 - 20.00 Schering-Plough Satellite Symposium	18.30 - 20.00 Bristol-Myers Squibb Satellite Symposium								

	Hall 1	Hall 2	Hall 15.2	Hall 3	Hall 15,1	Hall 15.3	Stage	Roof Garden	Hall 7	Hall 14.2	Hall 4/5	Hall 9	Hall 10	Hall 8
	<b>HIGHLIGHTS</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>	<b>T. L.</b>
08:00	<b>Breast Cancer, Colorectal Cancer, Lung Cancer</b>	<b>Breast</b> Late cardiac and carcinogenic effects of radiotherapy	<b>Colorectal</b> Screening for colorectal cancer, where are we now?	<b>Lung</b> Treatment of limited disease-SCLC	<b>Gynaecological</b> Endometriosis and cancer	<b>Radiotherapy</b> IMRT and other advances in radiotherapy in prostate cancer	<b>Nursing</b> Evaluation of quality indicators for cancer services	<b>GU-other</b> Current treatment of high risk testis cancer	<b>Melanoma</b> How to perform translational research in melanoma	<b>Drug Devel.</b> Pharmacokinetics in oncology drug development	<b>Symptom science</b> Antimetetics: state of the art	<b>Basic science</b> Chromatin remodelling and cancer	<b>Young Oncol.</b> The challenge of interacting with patients	<b>Surgical oncol.</b> An update of sentinel node biopsy on breast cancer
08:45	<b>Sc. S.</b>	<b>Spec. S.</b>	<b>Joint symposium</b>	<b>Sc. S.</b>	<b>Sc. S.</b>	<b>P. P.</b>	<b>Sc. S.</b>	<b>Soc. S.</b>	<b>Sc. S.</b>	<b>P. P.</b>		<b>Sc. S.</b>	<b>Sc. S.</b>	<b>Sc. S.</b>
09:00	<b>Breast</b>	ESMO	<b>ECCO-ASCO</b>	<b>Oncopolicy</b>	<b>Gynaecological</b>	<b>Noncolorectal</b>	<b>Nursing</b>	<b>ESSO</b>	<b>Melanoma</b>	<b>Drug Devel.</b>		<b>Imaging</b>	<b>Young Oncol.</b>	<b>Paediatric</b>
11:00	Is cytotoxic treatment outdated in advanced or early breast cancer	ESMO Clinical guidelines recommendation	Controversies in individualised management of prostate cancer	High level Pharmaceutical forum recommendation	New targets for ovarian cancer	Proffered papers	Divergence within cancer nursing roles	European Society of Surgical Oncology	Current avenues in clinical trials for melanoma treatment	Proffered papers		Molecular imaging in cancer	FLIMS Symposium and ECCO/EJC award	New imaging approaches to response assessment
11:15	<b>Keynote</b>		<b>GU-renal</b>	<b>Radiotherapy</b>							<b>Symptom science</b>			
12:00	Insights into the cancer cell, stem cell interface through systems		Poster discussion (Viewing: 09:30-11:00)	Poster discussion (Viewing: 09:30-11:00)							Poster discussion (Viewing: 09:30-11:00)			
12:30	<b>Presidential III</b>													
13:30	<b>Awards, Late breaking and best abstracts</b>		<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Debate</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Spec. S.</b>	<b>Debate</b>
14:30			<b>GU-other</b>	<b>Gynaecological</b>	<b>Radiotherapy</b>	<b>Translational</b>	<b>Nursing</b>	<b>Surgical oncol.</b>	<b>Melanoma</b>	<b>Epidemiology</b>	<b>Regulatory</b>	<b>Sarcoma</b>	<b>Young Oncol.</b>	<b>Paediatric</b>
14:45			What is new in the pathogenesis of urothelial cancer ?	Immune system and ovarian cancers	Cancer stem cells and radiation resistance	Imaging in drug development	Using evidence-based cancer nursing practice	Sentinel node staging and clinical implications in GI tract	This house believes that adjuvant treatment should be the standard in stage II-III melanoma	Defining optimal strategies for HPV vaccination	Spec. S. on regulatory issues	Sarcoma orientated networks of excellence in Europe II	Oncology Societies: why?	This house believes that teenage and young adult units improve outcomes
14:45	<b>E.S.</b>	<b>E.S.</b>	<b>Sc. S.</b>	<b>Sc. S.</b>	<b>Sc. S.</b>	<b>Sc. S.</b>	<b>Soc. S.</b>	<b>Sc. S.</b>	<b>P. P.</b>	<b>Sc. S.</b>	<b>Sc. S.</b>	<b>Sc. S.</b>	<b>Sc. S.</b>	<b>Sc. S.</b>
16:45	<b>Basic science</b>	<b>General</b>	<b>Colorectal</b>	<b>Lung</b>	<b>GU-other</b>	<b>Radiotherapy</b>	<b>EONS</b>	<b>Translational</b>	<b>Melanoma</b>	<b>Epidemiology</b>	<b>Symptom science</b>	<b>Sarcoma</b>	<b>Young Oncol.</b>	<b>Paediatric</b>
17:00	Oncogenes revisited	Advances in Neuroendocrine cancers	Liver metastases from colorectal cancer	Management of malignant pleural mesothelioma	What are the side effects of therapy in mRCC and how to handle them?	Targeting in radiotherapy	The Future is ambulatory care	Targeting tumour cell signalling	Proffered papers	Cancer prevention in Europe	Symptom management	Special therapies for special sarcoma subtypes	Innovations in early clinical trials	Advances in Leukemia
17:00	<b>Debate</b>	<b>Debate</b>	<b>Debate</b>	<b>Spec. S.</b>	<b>Debate</b>	<b>Spec. S.</b>	<b>Debate</b>				<b>Debate</b>			
18:00	<b>Lung</b>	<b>GU-other</b>	<b>Radiotherapy</b>	<b>Breast</b>	<b>Translational</b>	<b>Drug Devel.</b>	<b>Nursing</b>	<b>Noncolorectal</b>		<b>Basic/Translational</b>	<b>Regulatory</b>			
	This house believes that targeted treatment should be used in all cases with lung cancer	This house believes that sequential use of TKIs does make sense in renal cancer	This house believes that hypofractionation should be a standard of care in breast cancer	Poster discussion (Viewing: 15:15-16:45)	Circulating tumour cells	This house believes that Phase II trials are a waste of time and money	Case-based: Leadership and management	This house believes that upfront chemoradiotherapy is a valid option in locally-advanced pancreatic cancer		Poster discussion (Viewing: 15:15-16:45)	This house believes that genomic signatures will be useful for personalised medicine			
														<b>Nursing poster viewing (09:00-17:00)</b>

18.30 - 20.00  
PharmaMar SA  
Satellite  
Symposium

18.30 - 20.00  
Mereck Serono  
Satellite  
Symposium

18.30 - 20.00  
Amgen (Europe)  
GmbH Satellite  
Symposium

18.30 - 20.00  
Vifor Pharma  
Satellite  
Symposium

18.30 - 20.00  
Abraxis  
Bioscience  
Satellite  
Symposium

	Hall 1	Hall 2	Hall 15.2	Hall 3	Hall 15,1	Hall 15.3	Stage	Roof Garden	Hall 7	Hall 14.2	Hall 4/5	Hall 9	Hall 10	Hall 8	
08:00		<b>HIGHLIGHTS</b>	<b>T. L.</b> <b>Breast</b>		<b>T. L.</b> <b>Noncolorectal</b>	<b>T. L.</b> <b>Radiotherapy</b>		<b>T. L.</b> <b>Nursing</b>	<b>T. L.</b> <b>Gynaecological</b>	<b>T. L.</b> <b>Imaging</b>	<b>T. L.</b> <b>Surgical oncol.</b>	<b>T. L.</b> <b>Sarcoma</b>	<b>T. L.</b> <b>Young Oncol.</b>		
08:45		GI-Noncolorectal, Melanoma, Drug Development	Special features of lobular cancer implications for management		Current standards and options in the treatment of squamous cell oesophageal cancer	Personalized radiotherapy: what's evidence-based?		Psycho-science: where do we go from here?	Overview of cervical cancer vaccination	How to use functional imaging info for radiotherapy planning	T1/T2 rectal cancer treatment	How to choose your treatment options for desmoids	Evidence based medicine: development and implementation of treatment guidelines in oncology		
09:00		<b>Sc. S.</b> <b>Breast</b>	<b>E. S.</b> <b>Drug Devel.</b>	<b>E. S.</b> <b>Oncopolicy</b>	<b>Sc. S.</b> <b>Noncolorectal</b>	<b>P.P.</b> <b>Radiotherapy</b>	<b>Sc. S.</b> <b>Nursing</b>	<b>P.P.</b> <b>Gynaecological</b>	<b>Spec. S.</b> <b>ESMO</b>	<b>P.P.</b> <b>Basic/Translational</b>	<b>Sc. S.</b> <b>Regulatory</b>	<b>P.P.</b> <b>Sarcoma</b>	<b>Sc. S.</b> <b>Young Oncol.</b>	<b>Sc. S.</b> <b>Symptom science</b>	<b>P. S. VII</b>
09:30	<b>Presidential IV</b>	Optimizing therapy of very young women with early breast cancer	Management and interpretation of novel toxicities of molecular targeted therapies	Chemoprevention of major cancers: the latest news	New directions in the treatment of gastric cancer	Profferd papers	Fertility and sexuality: the development of onco-sexology	Proffered papers	Current challenges of biopharmaceuticals and regulatory recommendations	Proffered papers	Monitoring and management of adverse drug events	Proffered papers	Multidisciplinary teams in cancer care	Communication crises in oncology	Paediatric Oncology, Public Health, Health Economics, Policy, Epidemiology, Prevention, Imaging
11:00	Awards, Late breaking and best abstracts														
11:15		<b>Spec. S.</b> <b>Breast</b>		<b>Spec. S.</b> <b>Oncopolicy</b>	<b>Spec. S.</b> <b>Noncolorectal</b>	<b>Spec. S.</b> <b>Radiotherapy</b>	<b>Spec. S.</b> <b>Nursing</b>	<b>Spec. S.</b> <b>Basic science</b>	<b>Spec. S.</b> <b>Epidemiology</b>	<b>Spec. S.</b> <b>Imaging</b>	<b>Spec. S.</b> <b>Regulatory</b>	<b>Spec. S.</b> <b>Sarcoma</b>	<b>Spec. S.</b> <b>Young Oncol.</b>	<b>Spec. S.</b> <b>Surgical oncol.</b>	
12:15		Locoregional control of breast cancer		Drug and lifestyle mediated prevention initiatives in Europe	Endoscopic treatment of gastroesophageal cancer	new approaches for evidence generation of novel radiation technologies	Future trends and EONS projects	Mouse models of cancer	Clinical implications of new discoveries in cancer genetics	Established and emerging imaging applications	Trial methodology	Sarcomas in adolescents	Career development opportunities after your degree	Lymphadenectomy for GI cancer-does it make a difference?	
12:30	<b>Presidential V</b>														
14:30		Highlights of 2009													